title: BEP for high-risk gestational trophoblastic tumor: results from a cohort of 45 patients.
abstract: OBJECTIVE
  To evaluate the effectiveness and safety of combination chemotherapy of bleomycin, etoposide, and cisplatin (BEP) regimen in patients with high-risk gestational trophoblastic neoplasia (GTN).
  
  
  METHODS
  The authors analyzed the clinical response, toxicity, and the occurrence of secondary tumors of 45 patients with high-risk GTN under BEP.
  
  
  RESULTS
  The total complete remission (CR) rate of BEP regimen was 88.89% (40/45). Five patients developed drug-resistance after average 4.8 courses of BEP, and the regimen converted to etoposide, methotrexate, and dactinomycin (EMA)/cyclophosphamide and vincristine sulfate (CO). Ultimately, four cases achieved CR and one case died of cancer. There were no severe anaphylaxis and obvious impairment of cardiac, liver, pulmonary and kidney function, except one patient who developed grade IV bone marrow suppression and worsened pulmonary fibrosis after chemotherapy. None of survival patients developed secondary tumor during the follow-up.
  
  
  CONCLUSIONS
  For young high-risk GTN patients, BEP may represent a safe and effective regimen.
authors.forename: S Q
authors.initials: SQ
authors.lastname: Song
authors.forename: C
authors.initials: C
authors.lastname: Wang
authors.forename: G N
authors.initials: GN
authors.lastname: Zhang
authors.forename: Y
authors.initials: Y
authors.lastname: Shi
authors.forename: Y
authors.initials: Y
authors.lastname: Zhu
authors.forename: T
authors.initials: T
authors.lastname: Hu
authors.forename: S Q
authors.initials: SQ
authors.lastname: Xu
authors.forename: Z R
authors.initials: ZR
authors.lastname: Yang
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D015331:Cohort Studies; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin